280 related articles for article (PubMed ID: 11708594)
1. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(43):960. PubMed ID: 11708594
[TBL] [Abstract][Full Text] [Related]
2. Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(45):1014-6. PubMed ID: 11724160
[TBL] [Abstract][Full Text] [Related]
3. From the Centers for Disease Control and Prevention. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
JAMA; 2001 Nov; 286(19):2396-7. PubMed ID: 11759668
[No Abstract] [Full Text] [Related]
4. Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(47):1051-4. PubMed ID: 11808926
[TBL] [Abstract][Full Text] [Related]
5. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
[TBL] [Abstract][Full Text] [Related]
6. Post-exposure anthrax prophylaxis.
Med Lett Drugs Ther; 2001 Oct; 43(1116-1117):91-2. PubMed ID: 11689760
[No Abstract] [Full Text] [Related]
7. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Oct; 50(42):909-19. PubMed ID: 11699843
[TBL] [Abstract][Full Text] [Related]
8. Increased US prescription trends associated with the CDC Bacillus anthracis antimicrobial postexposure prophylaxis campaign.
Shaffer D; Armstrong G; Higgins K; Honig P; Coyne P; Boxwell D; Beitz J; Leissa B; Murphy D
Pharmacoepidemiol Drug Saf; 2003; 12(3):177-82. PubMed ID: 12733470
[TBL] [Abstract][Full Text] [Related]
9. Post-exposure anthrax prophylaxis.
Conn Med; 2001 Dec; 65(12):721-2. PubMed ID: 11797483
[No Abstract] [Full Text] [Related]
10. [Tetracyclines and ciprofloxacin as treatment for children and pregnant or lactating women in the era of biological terror].
Aizenstien O; Lehavi O; Sagi R
Harefuah; 2002 May; 141 Spec No():100-4, 119, 118. PubMed ID: 12170543
[TBL] [Abstract][Full Text] [Related]
11. Interim guidelines for investigation of and response to Bacillus anthracis exposures.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(44):987-90. PubMed ID: 11724154
[TBL] [Abstract][Full Text] [Related]
12. Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(44):973-6. PubMed ID: 11724150
[TBL] [Abstract][Full Text] [Related]
13. Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001.
Williams JL; Noviello SS; Griffith KS; Wurtzel H; Hamborsky J; Perz JF; Williams IT; Hadler JL; Swerdlow DL; Ridzon R
Emerg Infect Dis; 2002 Oct; 8(10):1133-7. PubMed ID: 12396928
[TBL] [Abstract][Full Text] [Related]
14. Update: Investigation of bioterrorism-related anthrax, 2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(45):1008-10. PubMed ID: 11724158
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous anthrax as an occupational disease in Central Anatolia, Turkey.
Yetkin MA; Erdinc FS; Bulut C; Tulek N
Saudi Med J; 2006 May; 27(5):737-9. PubMed ID: 16680276
[No Abstract] [Full Text] [Related]
16. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence.
Shepard CW; Soriano-Gabarro M; Zell ER; Hayslett J; Lukacs S; Goldstein S; Factor S; Jones J; Ridzon R; Williams I; Rosenstein N;
Emerg Infect Dis; 2002 Oct; 8(10):1124-32. PubMed ID: 12396927
[TBL] [Abstract][Full Text] [Related]
17. Update: investigation of bioterrorism-related inhalational anthrax--Connecticut, 2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(47):1049-51. PubMed ID: 11808925
[TBL] [Abstract][Full Text] [Related]
18. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.
Tierney BC; Martin SW; Franzke LH; Marano N; Reissman DB; Louchart RD; Goff JA; Rosenstein NE; Sever JL; McNeil MM;
Clin Infect Dis; 2003 Oct; 37(7):905-11. PubMed ID: 13130401
[TBL] [Abstract][Full Text] [Related]
19. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
Vietri NJ; Purcell BK; Tobery SA; Rasmussen SL; Leffel EK; Twenhafel NA; Ivins BE; Kellogg MD; Webster WM; Wright ME; Friedlander AM
J Infect Dis; 2009 Feb; 199(3):336-41. PubMed ID: 19099484
[TBL] [Abstract][Full Text] [Related]
20. Management of asymptomatic pregnant or lactating women exposed to anthrax.
Committee on Obstetric Practice
Int J Gynaecol Obstet; 2002 Jun; 77(3):293-5. PubMed ID: 12150144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
